tbuckley/cabot-search huggingface dataset:
Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells
Authors: Gregory P Botta, Joseph Chao, Hong Ma, Michael Hahn, Gloria Sierra, Jie Jia, Amanda Y Hendrix, Joy V Nolte Fong, Audrey Ween, Peter Vu, Aaron Miller, Michael Choi, Benjamin Heyman, Gregory A Daniels, Dan Kaufman, Catriona Jamieson, Zonghai Li, Ezra Cohen
Journal: Journal for ImmunoTherapy of Cancer (2024)

Treatment of hematologic malignancies with patient-derived anti-CD19 chimeric antigen receptor (CAR) T-cells has demonstrated long-term remissions for patients with otherwise treatment-refractory advanced leukemia and lymphoma. Conversely, CAR T-cell treatment of solid tumors, including advanced gastric cancer (GC), has proven more challenging due to on-target off-tumor toxicities, poor tumor T-cell infiltration, inefficient CAR T-cell expansion, immunosuppressive tumor microenvironments, and demanding preconditioning regimens. We report the exceptional results of autologous Claudin18.2-targeted CAR T cells (CT041) in a patient with metastatic GC, who had progressed on four lines of combined systemic chemotherapy and immunotherapy. After two CT041 infusions, the patient had target lesion complete response and sustained an 8-month overall partial response with only minimal ascites. Moreover, tumor-informed circulating tumor DNA (ctDNA) reductions coincided with rapid CAR T-cell expansion and radiologic response. No severe toxicities occurred, and the patient's quality of life significantly improved. This experience supports targeting Claudin18.2-positive GC with CAR T-cell therapy and helps to validate ctDNA as a biomarker in CAR T-cell therapy.
Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
Authors: Raul D. Santos, Albert Wiegman, Sonia Caprio, Bertrand Cariou, Maurizio Averna, Yann Poulouin, Michel Scemama, Garen Manvelian, Genevieve Garon, Stephen Daniels
Journal: JAMA Pediatrics (2024)

Importance Many pediatric patients with heterozygous familial hypercholesterolemia (HeFH) cannot reach recommended low-density lipoprotein cholesterol (LDL-C) concentrations on statins alone and require adjunct lipid-lowering therapy (LLT); the use of alirocumab in pediatric patients requires evaluation. Objective To assess the efficacy of alirocumab in pediatric patients with inadequately controlled HeFH. Design, Setting, and Participants This was a phase 3, randomized clinical trial conducted between May 2018 and August 2022 at 43 centers in 24 countries. Pediatric patients aged 8 to 17 years with HeFH, LDL-C 130 mg/dL or greater, and receiving statins or other LLTs were included. Following consecutive enrollment into dosing cohorts, 25 of 99 patients screened for dosing every 2 weeks (Q2W) failed screening; 25 of 104 patients screened for dosing every 4 weeks (Q4W) failed screening. A total of 70 of 74 Q2W patients (95%) and 75 of 79 Q4W patients (95%) completed the double-blind period. Interventions Patients were randomized 2:1 to subcutaneous alirocumab or placebo and Q2W or Q4W. Dosage was based on weight (40 mg for Q2W or 150 mg for Q4W if &amp;amp;lt;50 kg; 75 mg for Q2W or 300 mg for Q4W if ≥50 kg) and adjusted at week 12 if LDL-C was 110 mg/dL or greater at week 8. After the 24-week double-blind period, patients could receive alirocumab in an 80-week open-label period. Main Outcomes and Measures The primary end point was percent change in LDL-C from baseline to week 24 in each cohort. Results Among 153 patients randomized to receive alirocumab or placebo (mean [range] age, 12.9 [8-17] years; 87 [56.9%] female), alirocumab showed statistically significant reductions in LDL-C vs placebo in both cohorts at week 24. Least squares mean difference in percentage change from baseline was −43.3% (97.5% CI, −56.0 to −30.7; P &amp;amp;lt; .001) Q2W and −33.8% (97.5% CI, −46.4 to −21.2; P &amp;amp;lt; .001) Q4W. Hierarchical analysis of secondary efficacy end points demonstrated significant improvements in other lipid parameters at weeks 12 and 24 with alirocumab. Two patients receiving alirocumab Q4W experienced adverse events leading to discontinuation. No significant difference in adverse event incidence was observed between treatment groups. Open-label period findings were consistent with the double-blind period. Conclusions and Relevance The findings in this study indicate that alirocumab Q2W or Q4W significantly may be useful for reducing LDL-C and other lipid parameters and be well tolerated in pediatric patients with HeFH inadequately controlled with statins. Trial Registration ClinicalTrials.gov Identifier: NCT03510884
Early Correlates of School Readiness Before and During the COVID-19 Pandemic Linking Health and School Data
Authors: Kristen A. Copeland, Lauren Porter, Michelle C. Gorecki, Allison Reyner, Cynthia White, Robert S. Kahn
Journal: JAMA Pediatrics (2024)

Many known correlates of kindergarten readiness are captured in developmental and social screenings in primary care; little is known about how primary care data predicts school readiness.
Considerations in Early Autism Diagnosis—Reply
Authors: Elizabeth Harstad, William Barbaresi
Journal: JAMA Pediatrics (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
ST-T Alternans in Acute Myocardial Infarction as a Risk Predictor for Fatal Ventricular Arrhythmia—Reply
Authors: Liugang Xu, Yajun Wang, Hailei Liu
Journal: JAMA Internal Medicine (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Risk of Stroke and Myocardial Infarction Among Initiators of Triptans
Authors: Christian Lund Petersen, Anders Hougaard, David Gaist, Jesper Hallas
Journal: JAMA Neurology (2024)

Triptans are contraindicated in patients with ischemic heart disease or previous myocardial infarction, and caution is advised when prescribing these drugs to patients with vascular risk factors. However, controlled observational studies have either shown no association or an apparent lower risk, possibly owing to a channeling of triptans to individuals at low risk of cardiovascular outcomes, and it remains unclear whether avoiding triptan treatment for these patients is meaningful.
ST-T Alternans in Acute Myocardial Infarction as a Risk Predictor for Fatal Ventricular Arrhythmia
Authors: Yun-Tao Zhao, Lei Wang
Journal: JAMA Internal Medicine (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Delivery Device Patents on GLP-1 Receptor Agonists
Authors: Rasha Alhiary, Sarah Gabriele, Aaron S. Kesselheim, S. Sean Tu, William B. Feldman
Journal: JAMA (2024)

This study analyzed the US Food and Drug Administration–listed patents on glucagon-like peptide 1 (GLP-1) receptor agonists to determine their claim characteristics and the potential barriers they pose to generic entry.
Communities Reverberate From the Harm by Law Enforcement to Unarmed Black Persons
Authors: Giselle Corbie, Raegan W. Durant, Mitchell H. Katz
Journal: JAMA Internal Medicine (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
KBTBD13 is an actin-binding protein that modulates muscle kinetics
Authors: Josine M. de Winter, Joery P. Molenaar, Michaela Yuen, Robbert van der Pijl, Shengyi Shen, Stefan Conijn, Martijn van de Locht, Menne Willigenburg, Sylvia J.P. Bogaards, Esmee S.B. van Kleef, Saskia Lassche, Malin Persson, Dilson E. Rassier, Tamar E. Sztal, Avnika A. Ruparelia, Viola Oorschot, Georg Ramm, Thomas E. Hall, Zherui Xiong, Christopher N. Johnson, Frank Li, Balazs Kiss, Noelia Lozano-Vidal, Reinier A. Boon, Manuela Marabita, Leonardo Nogara, Bert Blaauw, Richard J. Rodenburg, Benno Küsters, Jonne Doorduin, Alan H. Beggs, Henk Granzier, Ken Campbell, Weikang Ma, Thomas Irving, Edoardo Malfatti, Norma B. Romero, Robert J. Bryson-Richardson, Baziel G.M. van Engelen, Nicol C. Voermans, Coen A.C. Ottenheijm
Journal: Journal of Clinical Investigation (2024)
Circadian immunity from bench to bedside: a practical guide
Authors: Huram Mok, Elaine Ostendorf, Alex Ganninger, Avi J. Adler, Guy Hazan, Jeffrey A. Haspel
Journal: Journal of Clinical Investigation (2024)

The immune system is built to counteract unpredictable threats, yet it relies on predictable cycles of activity to function properly. Daily rhythms in immune function are an expanding area of study, and many originate from a genetically based timekeeping mechanism known as the circadian clock. The challenge is how to harness these biological rhythms to improve medical interventions. Here, we review recent literature documenting how circadian clocks organize fundamental innate and adaptive immune activities, the immunologic consequences of circadian rhythm and sleep disruption, and persisting knowledge gaps in the field. We then consider the evidence linking circadian rhythms to vaccination, an important clinical realization of immune function. Finally, we discuss practical steps to translate circadian immunity to the patient's bedside.
Should I stay or should I go? Transsulfuration influences invasion and growth in glioblastoma
Authors: András K. Ponti, Daniel J. Silver, Christopher Hine, Justin D. Lathia
Journal: Journal of Clinical Investigation (2024)

A major challenge in treating patients with glioblastoma is the inability to eliminate highly invasive cells with chemotherapy, radiation, or surgical resection. As cancer cells face the issue of replicating or invading neighboring tissue, they rewire their metabolism in a concerted effort to support necessary cellular processes and account for altered nutrient abundance. In this issue of the JCI, Garcia et al. compared an innovative 3D hydrogel–based invasion device to regional patient biopsies through a comprehensive multiomics-based approach paired with a CRISPR knockout screen. Their findings elucidate a role for cystathionine γ-lyase (CTH), an enzyme in the transsulfuration pathway, as a means of regulating the cellular response to oxidative stress. CTH-mediated conversion of cystathionine to cysteine was necessary for regulating reactive oxygen species to support invasion. Meanwhile, inhibition of CTH suppressed the invasive glioblastoma phenotype. However, inhibiting CTH resulted in a larger overall tumor mass. These findings suggest that targeting the transsulfuration pathway may serve as a means of redirecting glioblastoma to proliferate or invade.
News beyond our pages
Journal: Journal of Allergy and Clinical Immunology (2024)

Continued on next page TCR-specific T-cell immunotherapy in autoimmune diseaseCD8 + T cells with T-cell receptors (TCRs) containing the TCR beta variable 9 (TRBV9) peptide have been linked to the development of multiple HLA-B*27-associated spondyloarthropathies, including ankylosing spondylitis.
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings
Authors: Murielle M. Véniant, Shu-Chen Lu, Larissa Atangan, Renee Komorowski, Shanaka Stanislaus, Yuan Cheng, Bin Wu, James R. Falsey, Todd Hager, Veena A. Thomas, Malhar Ambhaikar, Lucie Sharpsten, Yineng Zhu, Vamsi Kurra, Rohini Jeswani, Rajneet K. Oberoi, Jane R. Parnes, Narimon Honarpour, Joel Neutel, Jennifer L. Strande
Journal: Nature Metabolism (2024)

Abstract Obesity is a major public health crisis. Multi-specific peptides have emerged as promising therapeutic strategies for clinical weight loss. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are endogenous incretins that regulate weight through their receptors (R). AMG 133 (maridebart cafraglutide) is a bispecific molecule engineered by conjugating a fully human monoclonal anti-human GIPR antagonist antibody to two GLP-1 analogue agonist peptides using amino acid linkers. Here, we confirm the GIPR antagonist and GLP-1R agonist activities in cell-based systems and report the ability of AMG 133 to reduce body weight and improve metabolic markers in male obese mice and cynomolgus monkeys. In a phase 1, randomized, double-blind, placebo-controlled clinical study in participants with obesity ( NCT04478708 ), AMG 133 had an acceptable safety and tolerability profile along with pronounced dose-dependent weight loss. In the multiple ascending dose cohorts, weight loss was maintained for up to 150 days after the last dose. These findings support continued clinical evaluation of AMG 133.
The androgen receptor interacts with GATA3 to transcriptionally regulate a luminal epithelial cell phenotype in breast cancer
Authors: Leila Hosseinzadeh, Zoya Kikhtyak, Geraldine Laven-Law, Stephen M. Pederson, Caroline G. Puiu, Clive S. D’Santos, Elgene Lim, Jason S. Carroll, Wayne D. Tilley, Amy R. Dwyer, Theresa E. Hickey
Journal: Genome biology (2024)

The androgen receptor (AR) is a tumor suppressor in estrogen receptor (ER) positive breast cancer, a role sustained in some ER negative breast cancers. Key factors dictating AR genomic activity in a breast context are largely unknown. Herein, we employ an unbiased chromatin immunoprecipitation-based proteomic technique to identify endogenous AR interacting co-regulatory proteins in ER positive and negative models of breast cancer to gain new insight into mechanisms of AR signaling in this disease.
Untargeted Metabolomic Profiling Of Asthma Severity In Children In Relation To IL4R576 Variant Genotype And Notch4 expression
Authors: Hani Harb, Mehdi Benamar, Rima Kaddurah-Daouk, Wanda Phipatanakul, Talal Chatila, Elena Crestani
Journal: Journal of Allergy and Clinical Immunology (2024)
Dupilumab Reduction of IgE Levels and Probability of Atopic Dermatitis Flares – Analysis of A Randomized Placebo-Controlled 52-Week Study
Authors: Brian Kim, Lisa Beck, Eric Simpson, Lawrence Eichenfield, Jonathan Silverberg, Kilian Eyerich, Shinichi Imafuku, Zhen Chen, Ana Rossi, Sonya Cyr
Journal: Journal of Allergy and Clinical Immunology (2024)
Using 15-Oxo-ETE for Risk Stratifying Aspirin Hypersensitivity in Asthma Patients
Authors: Lucyna Mastalerz, Gabriela Trąd, Piotr Szatkowski, Radosław Kacorzyk, Alicja Maciejska, Anna Gielicz, Hanna Plutecka, Bogdan Jakieła, Adam Ćmiel, Marek Sanak
Journal: Journal of Allergy and Clinical Immunology (2024)
Mono-n-butyl Phthalate Affects To The Development Of Atopic Dermatitis In Children Via Alteration Of Linoleic Acid Metabolism: ECHO-COCOA Study
Authors: Mi-Jin Kang, Hyun Ju Yoo, Hosub Im, Selim Oh, Yong Joo Park, Hoon Je Seong, Jeonghun Yeom, Song I. Yang, Hyo-Bin Kim, Kangmo Ahn, Kyung Won Kim, Youn Ho Shin, Dong In Suh, So-Yeon Lee, Soo-Jong Hong
Journal: Journal of Allergy and Clinical Immunology (2024)
Dysregulated nasal mucosal antiviral transcriptome in young children with problematic wheeze infected with rhinovirus (RV)
Authors: Larry Borish, Ava Noth, Stella Kellams, Kristin Wavell, Elaine Etter, Cameron Griffiths, Monica Lawrence, Ryan Sessuns, Gerald Teague
Journal: Journal of Allergy and Clinical Immunology (2024)
ALLERGY TO NUTS AND ITS ASSOCIATION WITH OTHER PLANT-FOOD ALLERGENS IN THE ADULT MEDITERRANEAN POPULATION
Authors: Gabriela Aray, María Baeza, Sofia Proaño-Mosquera, Francesco Altuve-Giannini, Francisco De Castro, Elena Rodriguez-Mazariego, Gabriela Zambrano-Ibarra
Journal: Journal of Allergy and Clinical Immunology (2024)
Advanced fructo-oligosaccharides improve itching and aberrant epidermal lipid composition in children with atopic dermatitis.
Authors: Sehun Jang, Bae-Gon Kang, Soonok Sa, Se Young Park, Kyungheon Ryu, Jinyoung Lee, Boram Park, Jiwon Kim, Sanghee Shin, Jeongmin Song, Byung Eui Kim, Kangmo Ahn, Kwang-Hyeon Liu, Jihyun Kim
Journal: Journal of Allergy and Clinical Immunology (2024)
A Prospective Study of Intimate Partner Violence, Uncontrolled Asthma, and Inflammatory Pathways: Insights from Cytokine Profiles
Authors: Kelly Shibuya, Sadhana Balasubramanyam, Divya Verma, Kristen Holm, Rafeul Alam, Anne DePrince, Eileen Wang
Journal: Journal of Allergy and Clinical Immunology (2024)
REAL-LIFE EFFECTIVENESS OF MEPOLIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
Authors: Maria Gómez Viciana, Itziar Eusebio, Cristina Juárez, Maria Paixao, David Lora, Rocio Díaz-Campos, Consuelo Fernandez, Jesus Crespo, Ismael Garcia-Moguel
Journal: Journal of Allergy and Clinical Immunology (2024)
Remibrutinib Treatment Did Not Impact Total Serum Immunoglobulin Levels or Infection Rates in Patients With Chronic Spontaneous Urticaria: Phase 2b Study Results
Authors: Warner Carr, Ana GimÃ©nez-Armau, Karine Lheritier, Sibylle Haemmerle, Artem Zharkov, Swapnil Dahale, Koremasa Hayama, Robert Snyder
Journal: Journal of Allergy and Clinical Immunology (2024)
A Multicenter Investigation Of Chronic Cough Using An Electronic Questionnaire Survey
Authors: Alisa Gnaensky, Mahboobeh Mahdavinia, S. Shahzad Mustafa, Jill Poole, Mandel Sher, Raffi Tachdjian, Andrew White, Jonathan Bernstein, David Khan
Journal: Journal of Allergy and Clinical Immunology (2024)
Impact of soy isoflavones (genistein) on allergic asthma in epidemiologic and mouse models: national birth cohort in South Korea and murine model
Authors: Seong Cho, Jiyeon Oh, Jung Yeon Han, Minji Kim, Joong Cho, Susumu Fukahori, Jea-Young Lee, Richard Lockey, Rajesh Kumar, Dong Keon Yon
Journal: Journal of Allergy and Clinical Immunology (2024)
Propolis: Emerging Allergen in Facial Contact Dermatitis
Authors: Jasmine Abbosh, Nadine Behjet
Journal: Journal of Allergy and Clinical Immunology (2024)

We sought to investigate the frequency of positive patch tests to propolis (bee glue) in patients presenting with facial contact dermatitis. This was a retrospective review of patch test results of consecutive adult patients presenting with facial contact dermatitis tested between August 2022 and July 2023. Patch testing was performed using the American Core Patch Series (80 allergens). Twenty-one patients underwent testing. Seventeen (81%) had positive reactions to at least one allergen. The three most common positive allergens were to propolis found in seven patients (33%) followed by nickel in five (24%), and fragrance mix in four (19%). The most common site of skin involvement was eyelids. The mean age was forty-five with 95% females. Our results indicate a high prevalence of contact sensitization to propolis in adults presenting with facial contact dermatitis.
Garadacimab For Hereditary Angioedema Prophylaxis In Adolescents: Efficacy And Safety From The Phase 3 (VANGUARD) Study And Open-Label Extension (Second Interim Analysis)
Authors: Joshua Jacobs, Markus Magerl, Inmaculada Martinez-Saguer, Huamin Li, Jonathan Bernstein, Connie Hsu, Karl Sitz, Lolis Wieman, Henrike Feuersenger, Maressa Pollen, Avner Reshef
Journal: Journal of Allergy and Clinical Immunology (2024)
Dupilumab Consistently Reduces CCL-17 (TARC) in Patients with Atopic Dermatitis Across All Age Groups
Authors: Lisa Beck, Mark Boguniewicz, Yoko Kataoka, Marjolein de Bruin-Weller, Antonella Muraro, Zhen Chen, Ainara Rodriguez-Marco, Parul Shah, Ana Rossi
Journal: Journal of Allergy and Clinical Immunology (2024)
Dupilumab Improves Urticaria-Specific Quality of Life in Patients with Chronic Spontaneous Urticaria Uncontrolled by H1 Antihistamines
Authors: Marcus Maurer, Thomas Casale, Gil Yosipovitch, Sarbjit Saini, Moshe Ben-Shoshan, Lisa Beck, Jérôme Msihid, Philip Sugerman, Sonya Cyr, Ryan Thomas, Chien-Chia Chuang
Journal: Journal of Allergy and Clinical Immunology (2024)
Patient Reported Outcomes Measures (PROMs) in atopic dermatitis: perceptions and level of satisfaction.
Authors: Monika Fida, Natasa Teovska-Mitrevska, Magdalena Zajac, German Ramon, Luis Escalante, Astrid Maldonado, Edgar Escalante, Maria Touriz, Jaime Cardenas, Ivan Tinoco, Ana Ormaza Vera, Maria Osorio, Leonardo Cano, Belen Intriago, Karla Robles-Velasco, Marco Faytong-Haro, Andrzej Bozek
Journal: Journal of Allergy and Clinical Immunology (2024)